• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Thorac Res Pract . Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019

tetano

Editor, Senior Moderator
Thorac Res Pract


. 2023 Nov 28.
doi: 10.5152/ThoracResPract.2023.23001. Online ahead of print. Recovery from Respiratory Failure in Patients with Coronavirus Disease 2019

Miraç Öz[SUP] 1 [/SUP], Serhat Erol[SUP] 1 [/SUP], Aslıhan Gürün Kaya[SUP] 1 [/SUP], Özlem Işık[SUP] 1 [/SUP], Fatma Çiftci[SUP] 1 [/SUP], Güle Çınar[SUP] 2 [/SUP], Çağlar Uzun[SUP] 3 [/SUP], Alpay Azap[SUP] 3 [/SUP], Aydın Çiledağ[SUP] 1 [/SUP], Akın Kaya[SUP] 1 [/SUP], Özlem Özdemir Kumbasar[SUP] 1 [/SUP]



Affiliations
Abstract

Objective: Coronavirus disease 2019 (COVID-19) can cause hypoxic respiratory failure; long-term oxygen therapy (LTOT) duration is unknown.
Material and methods: The aim was to investigate which patients would need LTOT after COVID-19 pneumonia. This single-center, prospective study was conducted at the Ankara University Faculty of Medicine, Department of Chest Diseases, between May 2021 and December 2021. The 70 patients hospitalized for COVID-19 pneumonia and discharged with LTOT due to hypoxemic respiratory failure were included. Patients were divided into 2 groups as group I (LTOT requirement <3 months) and group II (LTOT requirement continued ≥3 months).
Results: The mean age was 64.4 ± 13.5 years, and 44 (62.9%) of them were male. The most frequently encountered comorbidities were cardiovascular disease (57.1%) and lung disease (22.9%). While PaO2 levels increased in both groups during the follow-up period, this increment was significantly higher in group I (PaO2: 66.6 ± 9.9 mm Hg, P < .001). The factors affecting the LTOT requirement were evaluated using binary logistic regression. On multivariate analyses of lymphocytes, ferritin, C-reactive protein, PaO2, SaO2, subpleural reticulation, and number of lobes affected (≥3 lobes), the SaO2 level and presence of subpleural reticulation were significantly different between the 2 groups [odds ratio (OR) (95% CI): 0.853 (0.749-0.971), P = .016] and [OR (95% CI): 0.171 (0.042-0.733), P = .017], respectively.
Conclusion: A significant proportion of patients who develop respiratory failure due to COVID-19 recover within the first 3 months. Factors determining the LTOT requirement for more than 3 months were SaO2 and the presence of subpleural reticulation.


 
Back
Top Bottom